Author

Y. Ban

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:bulk RNA-seq· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Organism:mouse· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 1

Frequent Co-Authors

A. Bianchi· 3 shared A. R. Dosch· 3 shared J. Datta· 3 shared N. Nagathihalli· 3 shared S. Mehra· 3 shared S. Singh· 3 shared I. De Castro Silva· 2 shared N. Merchant· 2 shared

Activity by Year

2021-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Bianchi

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

CREB drives acinar cells to ductal reprogramming and promotes pancreatic cancer progression in preclinical models of alcoholic pancreatitis

S. Srinivasan, S. Mehra, S. Jinka, A. Bianchi, S. Singh, A. R. Dosch, H. Amirian, V. Krishnamoorthy, I. D. C. Silva, M. Patel, E. W. Box, V. Garrido, T. M. Totiger, Z. Zhou, Y. Ban, , N. Nagathihalli

This study shows CREB promotes acinar-to-ductal reprogramming and pancreatic cancer progression in alcoholic pancreatitis models by enhancing fibrosis and tumor growth.

Cellular and Molecular Gastroenterology and Hepatology · Jan 1, 2025Peer-reviewedCancer Biology

Targeting Ribosome Biogenesis as a Novel Therapeutic Approach to Overcome EMT-related Chemoresistance in Breast Cancer.

Y. Ban, Y. Zou, Y. Liu, S. B. Lee, R. B. Bednarczyk, J. Sheng, Y. Cao, S. T. C. Wong, D. Gao

This study identifies ribosome biogenesis as a key driver of EMT/MET transitions in breast cancer and shows that targeting this pathway enhances chemotherapy efficacy against chemoresistant tumors.

bioRxiv · Jun 28, 2023Cancer Biology

Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with KRAS-TP53 Co-Alteration in Pancreatic Cancer

J. Datta, A. Bianchi, I. De Castro Silva, N. U. Deshpande, L. L. Cao, S. Mehra, S. Singh, C. Rafie, X. Sun, X. Chen, X. Dai, A. Colaprico, P. Sharma, A. R. Dosch, A. Pillai, , N. B. Merchant

bioRxiv · May 1, 2022Cancer Biology

Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancer

J. Datta, X. Dai, A. Bianchi, I. De Castro Silva, S. Mehra, V. T. Garrido, P. Lamichhane, S. Singh, Z. Zhou, A. R. Dosch, F. Messagio, Y. Ban, O. Umland, P. J. Hosein, N. Nagathihalli, N. Merchant

This paper shows that combining MEK and STAT3 inhibitors reprograms stromal inflammation and enhances immunotherapy response in pancreatic cancer.

bioRxiv · Mar 7, 2021 · PreprintCancer Biology

Derived loss of signal complexity and plasticity in a genus of weakly electric fish

D. E. Saenz, T. Gu, Y. Ban, K. O. Winemiller, M. R. Markham

This study compares EOD plasticity and physiology in Brachyhypopomus fish, finding that B. bennetti has minimal plasticity but retains vestigial mechanisms for biphasic signaling.

bioRxiv · Feb 6, 2021Physiology

LBH is a cancer stem cell- and metastasis-driving oncogene essential for WNT stem cell function in breast cancer

K. Garikapati, K. Ashad-Bishop, S. Hong, R. Qureshi, M. E. Rieger, L. E. Lindley, B. Wang, D. J. Azzam, M. Khanlari, M. Nadji, C. Jain, D. Kwon, Y. Ban, Z. Gao, S. X. Chen, , K. J. Briegel

This study identifies LBH as a key oncogene driving cancer stem cell function and metastasis in breast cancer through WNT pathway activation.

bioRxiv · Jan 29, 2021 · PreprintCancer Biology